The existing preclinical studies and clinical trial results collectively suggest that GPRC5D‐targeted CAR‐T cells offer significant potential for patients with multiple myeloma, particularly those who relapse following anti‐BCMA treatment. This evidence concerns the gene GPRC5D and plasma cell myeloma.